HOOKIPA Pharma Inc. (HOOKIPA) has announced a series of corporate actions involving its stock, including a reverse stock split, an increase in authorized shares, and a potential stock purchase by Gilead Sciences, Inc. The company's Board of Directors has approved an amendment to increase authorized common stock from 200 million to 400 million shares, subject to stockholder approval. Concurrently, stockholders are being asked to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-10, to be determined by the Board, with the aim of increasing the per-share trading price and maintaining NASDAQ listing requirements. Additionally, HOOKIPA entered into an amended stock purchase agreement with Gilead Sciences, allowing Gilead to purchase up to $35 million of HOOKIPA's common stock. The company's 2024 Annual Meeting of Stockholders is set to address these proposals, with the Board recommending stockholder approval for both the increase in authorized shares and the reverse stock split.

HOOKIPA Pharma Inc. (HOOKIPA) has announced a series of corporate actions involving its stock, including a reverse stock split, an increase in authorized shares, and a potential stock purchase by Gilead Sciences, Inc. The company's Board of Directors has approved an amendment to increase authorized common stock from 200 million to 400 million shares, subject to stockholder approval. Concurrently, stockholders are being asked to authorize a reverse stock split at a ratio between 1-for-2 and 1-for-10, to be determined by the Board, with the aim of increasing the per-share trading price and maintaining NASDAQ listing requirements. Additionally, HOOKIPA entered into an amended stock purchase agreement with Gilead Sciences, allowing Gilead to purchase up to $35 million of HOOKIPA's common stock. The company's 2024 Annual Meeting of Stockholders is set to address these proposals, with the Board recommending stockholder approval for both the increase in authorized shares and the reverse stock split.